Lipoprotein(a) Screening for Cardiovascular Disease

Recruiting at820 trial locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: Amgen

No Placebo Group

Trial Summary

What is the purpose of this trial?

The purpose of this study is to characterize the distribution of lipoprotein(a) (Lp(a)) levels among participants with a history of ASCVD as defined by their medical history and is 2-fold: * Evaluate the distribution of Lp(a) value in the overall participants with documented history of ASCVD * Evaluate the distribution of Lp(a) value in participants with documented history of ASCVD by demographics and regions

Research Team

MD

Principal Investigator

Amgen

Eligibility Criteria

This study is for people who have a history of cardiovascular disease caused by atherosclerosis. Participants must have signed an informed consent form and not be on any investigational drugs or lipoprotein apheresis within the last 3 months, nor should they require dialysis due to end-stage renal disease.

Inclusion Criteria

Signed informed consent

You have a history of atherosclerotic cardiovascular disease.

Exclusion Criteria

Participants known to be currently receiving investigational drug in a clinical study

You have end-stage kidney disease or need dialysis.

You have had a procedure to lower your Lp(a) levels within the last 3 months before joining the study.

Treatment Details

Interventions

• Lp(a) Screening (Other)

Trial Overview The trial is focused on screening levels of lipoprotein(a), also known as Lp(a), in individuals with documented heart and artery diseases from atherosclerosis. It aims to understand how Lp(a) levels vary across different demographics and regions among these patients.

Participant Groups

Group I: Participants with history of ASCVD Experimental Treatment 1 Intervention

Participants with history of ASCVD with known or unknown Lp(a) values.

Who Is Running the Clinical Trial?

Amgen

Lead Sponsor

Trials

1,508

Recruited

1,433,000+

Founded

1980

Headquarters

Thousand Oaks, USA

Known For

Human Therapeutics

Top Products

Enbrel, Prolia, Neulasta, Otezla

Robert A. Bradway

Amgen

Chief Executive Officer since 2012

MBA from Harvard Business School

Paul Burton

Amgen

Chief Medical Officer since 2023

MD from University of London, PhD in Molecular and Cellular Biology from Imperial College London